Nezulcitinib (TD-0903) 是一种吸入和肺选择性 pan-Janus kinase (JAK) 抑制剂。Nezulcitinib 可用于 COVID-19 相关急性肺损伤及氧合受损的研究。
| 生物活性 | Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation[1][2]. |
| IC50& Target[1][2] | |
体外研究
(In Vitro) | Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor[1][2].
|
| Clinical Trial | |
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
